Oxford BioMedica Announces Publication of ProSavin® Phase I/II Study in The Lancet — Pioneering data published in world-leading, peer-reviewed medical journal — — ProSavin® has demonstrated favourable safety, tolerability and long-term improvement…
Oxford, UK – 9 January 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, announces that John Dawson, Chief Executive Officer, will present a…
Oxford, UK – 6 January 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, announced the results of its General Meeting held today in…
Oxford, UK – 18 December 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, announces that it has signed an option agreement with GlaxoSmithKline…
Oxford, UK – 19 November 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it has signed a £5 million secured loan…
Oxford, UK – 19 November 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1…
— Newly developed, state-of-the-art analytical methods confirm the integrity and quality of Oxford BioMedica’s LentiVector® platform products — Oxford, UK – 17 October 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the…
— UK consortium wins £7.7 million total funding, of which £7.1 million awarded to Oxford BioMedica as lead member — — Funding to support the development of a centre of…
Click here to download the full 2013 interim results statement.Click here to download the 2013 interim results presentation. Oxford, UK – 29 August 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:…
— Phase I clinical trial for 5T4-targeted antibody therapy underway — Oxford, UK – 28 August 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company,…
— Funding to be received for the development of a novel therapeutic treatment to engineer corneas to resist graft rejection — Oxford, UK – 14 August 2013: Oxford BioMedica plc (“Oxford…
— Results from Phase II trial in prostate cancer published in Cancer Immunology, Immunotherapy — — Favourable tolerability and biomarker results — Oxford, UK – 29 July 2013: Oxford BioMedica (“Oxford…